Dialysate and Plasma Meropenem Concentrations in Continuous Intraperitoneal Regimen during Peritoneal-Dialysis-Related Peritonitis
2025

Meropenem Levels in Peritoneal Dialysis Patients

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): Srithongkul Thatsaphan, Raksasuk Sukit, Techajongnumchai Bulaporn, Sritippayawan Suchai, Koomanachai Pornpan

Primary Institution: Siriraj Hospital, Mahidol University, Bangkok, Thailand

Hypothesis

Continuous intraperitoneal administration of meropenem will achieve adequate drug levels in patients with peritoneal-dialysis-related peritonitis.

Conclusion

A loading dose of 500 mg of intraperitoneal meropenem followed by 125 mg/L every 6 hours is effective in maintaining adequate drug levels for treating peritoneal dialysis-related peritonitis.

Supporting Evidence

  • Four out of five patients responded positively to the treatment.
  • The mean maximum dialysate meropenem level was 158.1 mg/L.
  • Dialysate levels exceeded the minimal inhibitory concentration for resistant organisms throughout the study.

Takeaway

This study shows that giving a specific antibiotic directly into the belly can help treat infections in patients on dialysis.

Methodology

This was a prospective, descriptive study measuring plasma and dialysate meropenem levels in five patients with peritoneal dialysis-related peritonitis after administering a loading dose followed by continuous dosing.

Potential Biases

Potential bias due to the small sample size and lack of randomization.

Limitations

The study had a small sample size and included patients with varying types of infections, which may affect the generalizability of the results.

Participant Demographics

The mean age of participants was 59 years, with a mix of genders and varying causes of end-stage renal disease.

Digital Object Identifier (DOI)

10.1371/journal.pone.0312160

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication